1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Regnum Corp.

Regnum Corp.

RGMP
Regnum Corp.US flagOther OTC
0.00
USD
- -
- -
2,295.00Market Cap
Regnum Corp.
RGMP
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
-0.01
-0.03
-0.03
Basic EPS, GAAP
- -
- -
- -
- -
- -
-0.03
-0.04
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
-0.01
-0.02
-0.05
-0.06
Book Value per Share
- -
- -
- -
- -
-0.02
-0.05
-0.06
Tangible Book Value per Share
23
23
23
24
23
23
23
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
12.43
16.1
-564.76
-1,307.48
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
-1
-1
Net Income, GAAP
38.36
42
- -
- -
- -
- -
- -
Effective Tax Rate (%)
7.66
9.34
-577.46
-1,307.48
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
-1
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
-1
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
8.67
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'23
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
3
3
3

Working Capital

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'23
Total Current Assets
1
1
- -
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
1
- -
- -
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
54.26%
205.59%
Free Cash Flow
- -
927.09%
5,992.28%
Net Income, GAAP
- -
-266.92%
189.4%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
-0.01
2022
-0.01
-0.01
-0.01
- -
-0.03
2023
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
ZIOPHARM Oncology, Inc. (ZIOP)
Cassiopea S.p.A. (SKIN.SW)
Chinook Therapeutics, Inc. (KDNY)
Newron Pharmaceuticals S.p.A. (0QOI.L)
Guiyang Xintian Pharmaceutical Co.,Ltd. (002873.SZ)
Awakn Life Sciences Corp. (AWKN.NE)
Business
Regnum Corp. Regnum Corp. (RGMP) develops and commercializes therapeutics for rare and infectious diseases, targeting patient populations facing adherence challenges from dosing, tolerability, cost, or accessibility issues; its primary asset is the exclusive U.S. commercial rights to leronlimab (PRO 140), a monoclonal antibody CCR5 antagonist that blocks R5 strains of HIV from entering healthy cells as an entry inhibitor. The company, founded in 2016 and headquartered in New York, New York, operates primarily in the United States with a lean team of two employees and focuses on biopharmaceutical commercialization in HIV indications. As a subsidiary of Phoenixus AG, Regnum Corp. shifted its business model in April 2021 from entertainment content to biotech via a change of control under Phoenixus, which acquired majority ownership, and secured the leronlimab commercialization license through an assignment agreement with CytoDyn Inc. and SevenScore Pharmaceuticals in January 2022, entailing milestone payments, royalties, and supply terms while CytoDyn handles development and FDA approvals. In 2023, the company experienced leadership changes with the resignation of CEO and board member Anne Kirby.